Epizyme Inc
NASDAQ:EPZM
Epizyme Inc
Cash from Investing Activities
Epizyme Inc
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Epizyme Inc
NASDAQ:EPZM
|
Cash from Investing Activities
$89.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Epizyme Inc's Cash from Investing Activities?
Cash from Investing Activities
89.3m
USD
Based on the financial report for Jun 30, 2022, Epizyme Inc's Cash from Investing Activities amounts to 89.3m USD.
What is Epizyme Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-1%
Over the last year, the Cash from Investing Activities growth was 130%.